tert-Butyl 2,3-dihydro-1,4-benzoxazine-4-carboxylate

Catalog No.: 
ACFDWX429
CAS No.: 
212180-23-9
Molecular Formula: 
C13H17NO3
Molecular Weight: 
235.28
tert-Butyl 2,3-dihydro-1,4-benzoxazine-4-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg98%$166.00InquiryInquiry
250mg98%$310.00InquiryInquiry
1g98%$696.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 2,3-dihydro-1,4-benzoxazine-4-carboxylate
IUPAC Nametert-butyl 2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate
MDL No.MFCD21106086
Molecular FormulaC13H17NO3
Molecular Weight235.28
SMILESO=C(N1CCOC2=CC=CC=C12)OC(C)(C)C
InChI KeyOBHIVFAYYDULPQ-UHFFFAOYSA-N
Synonym4-(tert-butoxycarbonyl)-3,4-dihydro-2H-1,4-benzoxazine;tert-Butyl 2,3-dihydro-1,4-benzoxazine-4-carboxylate;4H-1,4-Benzoxazine-4-carboxylic acid, 2,3-dihydro-, 1,1-dimethylethyl ester
CAS No.212180-23-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACFDWX429 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACGPFU350 route compound structure diagram
    ACGPFU350186663-74-1In Stock
  2. Then
  3. ACFDWX429 route product structure diagram
    ACFDWX429212180-23-9
Inquiry

2. ACFDWX429 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACRKLP219 route compound structure diagram
    ACRKLP2195735-53-5In Stock
  4. Then
  5. ACFDWX429 route product structure diagram
    ACFDWX429212180-23-9
Inquiry

3. ACFDWX429 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACFDWX429 route product structure diagram
    ACFDWX429212180-23-9
Inquiry

Comments (0)